Randox exhibit diagnostic innovations at Oncology Congress

Diagnostic firm Randox Laboratories sent a delegation of scientists from its Biosciences Division to take part in the UK Exhibition of Oncology Excellence, which is taking place this week in Beijing and Guangzhou, China

The centrepiece of the UK-China Oncology Congress, the exhibition has been carefully curated to follow the “Science to Patient Pathway” for new therapies - from research to clinical trials, regulatory approval, manufacturing and distribution.

The Randox Biosciences team, during the Congress event, will join a range of cancer- related seminars, offering an opportunity to learn about and influence Chinese government policies and priorities, and explore the latest trends and hot topics in oncology.

Julie-Ann O’Hare, Sales and Marketing Director for Randox Biosciences, commented; “At Randox Biosciences we are actively seeking opportunities to strengthen business ties between the UK and China, and of course to showcase our innovative diagnostic capabilities to what is one of our most important and growing markets.

We continue to expand our business presence there thanks to the ongoing pipeline of novel tests

“We continue to expand our business presence there thanks to the ongoing pipeline of novel tests being produced from our innovative research and development programmes and enhanced manufacturing capabilities, including new facilities at the Randox Science Park in Northern Ireland.”

Exhibiting to a diverse audience of universities, hospitals, and laboratories responsible for prevention, diagnosis, treatment and care in oncology, Randox Biosciences have joined the exhibition to showcase their innovative diagnostic tests for bladder cancer and early detection of renal toxicity – including Chronic Kidney Disease and Acute Kidney Injury.

Julie-Ann continued; “We continue to offer an increasing range of innovative diagnostic biomarkers to the growing and dynamic biotechnology markets.

“The focus on the importance of scientific research in the patient pathway, in enabling cancer diagnoses as soon as possible, offers us the perfect platform to introduce to China our latest pioneering oncological tests, including our test for bladder cancer. This test can stratify patients with haemeaturia (blood in the urine), who are at high risk of bladder cancer - reducing the number of unnecessary cystoscopies carried out on patients identified as ‘low risk’, significantly reducing healthcare costs and improving the waiting times for haematuria patients.”

For further information about the UK-China Oncology Congress, please email info@randoxbiosciences.com

Companies